Duquesne Family Office executed a complete portfolio overhaul in Q3 2026. The $5.2 million filing listed 90 new positions, completely replacing prior holdings. Top concentrations include 632307104 at 16.6%, 457669307 at 5.7%, and 874039100 representing 5.4%.

Duquesne Family Office initiated several new positions in Q3 2026, targeting specific growth sectors. The largest new capital allocation, $865,000, went to Natera Inc., a company focused on diagnostic genetic testing. Duquesne added $296,000 to Insmed Inc., a biotech developing therapies for rare diseases. Taiwan Semiconductor Manufacturing Company received a $282,000 investment, placing a new bet on the foundational global chip industry. Amazon.com Inc. also entered the portfolio with a $239,000 purchase. These buys, though small relative to Druckenmiller’s typical concentrated positions, reveal initial stakes in high-growth, high-risk areas.

A common thread connects these seemingly disparate picks. Druckenmiller, known for forecasting liquidity 18 months out, appears to position for a future environment benefiting early-stage or re-accelerating technology and biotechnology. His new positions, including $264,000 in Ishares Inc. and $232,000 in Stmicroelectronics N.V., suggest a conviction Federal Reserve policy might create tailwinds for risk assets, even in smaller-cap, higher-beta names. Duquesne’s willingness to initiate stakes in specialized biotech alongside global semiconductor powerhouses and a broad-market ETF indicates a readiness to capitalize on shifting macro tides. Druckenmiller maintains extreme mental flexibility, quickly reversing positions as facts change; these new entries reflect a specific outlook for the coming year and a half.